We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioTelemetry (BEAT) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, BioTelemetry (BEAT - Free Report) closed at $67.54, marking a -1.03% move from the previous day. This move lagged the S&P 500's daily gain of 0.5%. Elsewhere, the Dow gained 0.54%, while the tech-heavy Nasdaq added 0.76%.
Coming into today, shares of the heart monitoring device maker had lost 10.22% in the past month. In that same time, the Medical sector gained 2.18%, while the S&P 500 gained 2.53%.
Wall Street will be looking for positivity from BEAT as it approaches its next earnings report date. The company is expected to report EPS of $0.43, up 10.26% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $104.29 million, up 10.36% from the year-ago period.
BEAT's full-year Zacks Consensus Estimates are calling for earnings of $1.86 per share and revenue of $439.74 million. These results would represent year-over-year changes of -4.12% and +10.08%, respectively.
It is also important to note the recent changes to analyst estimates for BEAT. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 4.68% higher within the past month. BEAT is currently a Zacks Rank #1 (Strong Buy).
In terms of valuation, BEAT is currently trading at a Forward P/E ratio of 36.62. Its industry sports an average Forward P/E of 20.23, so we one might conclude that BEAT is trading at a premium comparatively.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 51, which puts it in the top 20% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BEAT in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BioTelemetry (BEAT) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, BioTelemetry (BEAT - Free Report) closed at $67.54, marking a -1.03% move from the previous day. This move lagged the S&P 500's daily gain of 0.5%. Elsewhere, the Dow gained 0.54%, while the tech-heavy Nasdaq added 0.76%.
Coming into today, shares of the heart monitoring device maker had lost 10.22% in the past month. In that same time, the Medical sector gained 2.18%, while the S&P 500 gained 2.53%.
Wall Street will be looking for positivity from BEAT as it approaches its next earnings report date. The company is expected to report EPS of $0.43, up 10.26% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $104.29 million, up 10.36% from the year-ago period.
BEAT's full-year Zacks Consensus Estimates are calling for earnings of $1.86 per share and revenue of $439.74 million. These results would represent year-over-year changes of -4.12% and +10.08%, respectively.
It is also important to note the recent changes to analyst estimates for BEAT. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 4.68% higher within the past month. BEAT is currently a Zacks Rank #1 (Strong Buy).
In terms of valuation, BEAT is currently trading at a Forward P/E ratio of 36.62. Its industry sports an average Forward P/E of 20.23, so we one might conclude that BEAT is trading at a premium comparatively.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 51, which puts it in the top 20% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BEAT in the coming trading sessions, be sure to utilize Zacks.com.